

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/005350-2024>

Tender

## **NHS Framework - Blood Disorders including Haemophilia A and B - July 2024**

NHS England

F02: Contract notice

Notice identifier: 2024/S 000-005350

Procurement identifier (OCID): ocds-h6vhtk-043b0e

Published 19 February 2024, 11:12am

### **Section I: Contracting authority**

#### **I.1) Name and addresses**

NHS England

1st Floor, Quarry House, Quarry Hill

Leeds

LS2 7UE

#### **Contact**

Katie Noonan

#### **Email**

[katie.noonan@nhs.net](mailto:katie.noonan@nhs.net)

#### **Country**

United Kingdom

## **Region code**

UKE - Yorkshire and the Humber

## **Internet address(es)**

Main address

<https://www.england.nhs.uk//>

Buyer's address

<https://www.england.nhs.uk//>

## **I.3) Communication**

The procurement documents are available for unrestricted and full direct access, free of charge, at

<https://health-family.force.com/s/Welcome>

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

<https://health-family.force.com/s/Welcome>

Tenders or requests to participate must be submitted to the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

<https://health-family.force.com/s/Welcome>

## **I.4) Type of the contracting authority**

Ministry or any other national or federal authority

## **I.5) Main activity**

Health

---

## **Section II: Object**

### **II.1) Scope of the procurement**

#### **II.1.1) Title**

NHS Framework - Blood Disorders including Haemophilia A and B - July 2024

Reference number

CM/PHS/22/5561

#### **II.1.2) Main CPV code**

- 33600000 - Pharmaceutical products

#### **II.1.3) Type of contract**

Supplies

#### **II.1.4) Short description**

Project Title: NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A and B - July 2024

Offer reference number: CM/PHS/22/5561

Period of framework: 1 July 2024 to 30 April 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.

Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England

#### **II.1.5) Estimated total value**

Value excluding VAT: £1,168,000,000

#### **II.1.6) Information about lots**

This contract is divided into lots: Yes

Tenders may be submitted for all lots

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/01 Standard Half-life Recombinant Factor VIII

Lot No

1

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

### **II.2.4) Description of the procurement**

Standard Half-life Recombinant Factor VIII

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/02 Enhanced Half-life Recombinant Factor VIII

Lot No

2

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

#### **II.2.4) Description of the procurement**

CM/PHS/22/5561/02 Enhanced Half-life Recombinant Factor VIII

#### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

#### **II.2.6) Estimated value**

Value excluding VAT: £1

#### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

#### **II.2.10) Information about variants**

Variants will be accepted: No

#### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/03 Emicizumab

Lot No

3

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

### **II.2.4) Description of the procurement**

CM/PHS/22/5561/03 Emicizumab

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/04 eftrenonacog alfa (rFIX EHL)

Lot No



4

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

### **II.2.4) Description of the procurement**

CM/PHS/22/5561/04 eftrenonacog alfa (rFIX EHL)

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/05 albutrepenonacog alfa (rFIX EHL)

Lot No

5

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

### **II.2.4) Description of the procurement**

CM/PHS/22/5561/05 albutrepenonacog alfa (rFIX EHL)

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/06 nonacog beta pegol (rFIX EHL)

Lot No

6

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

### **II.2.4) Description of the procurement**

CM/PHS/22/5561/06 nonacog beta pegol (rFIX EHL)

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/07 rFIX - Standard Half Life

Lot No

7

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

#### **II.2.4) Description of the procurement**

CM/PHS/22/5561/07 rFIX - Standard Half Life

#### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

#### **II.2.6) Estimated value**

Value excluding VAT: £1

#### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

#### **II.2.10) Information about variants**

Variants will be accepted: No

#### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/08 Recombinant Factor VII

Lot No

8

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

### **II.2.4) Description of the procurement**

CM/PHS/22/5561/08 Recombinant Factor VII

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/09 Porcine Factor VIII - susoctocog alfa

Lot No



9

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

### **II.2.4) Description of the procurement**

CM/PHS/22/5561/09 Porcine Factor VIII - susoctocog alfa

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

## **II.2.10) Information about variants**

Variants will be accepted: No

## **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

## **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/10 Factor VIII Inhibitor Bypassing Fraction

Lot No

10

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

### **II.2.4) Description of the procurement**

CM/PHS/22/5561/10 Factor VIII Inhibitor Bypassing Fraction

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/11 Factor IX - High Purity Factor IX

Lot No

11

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

### **II.2.4) Description of the procurement**

CM/PHS/22/5561/11 Factor IX - High Purity Factor IX

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/12 Factor X

Lot No

12

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

#### **II.2.4) Description of the procurement**

CM/PHS/22/5561/12 Factor X

#### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

#### **II.2.6) Estimated value**

Value excluding VAT: £1

#### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

#### **II.2.10) Information about variants**

Variants will be accepted: No

#### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/13 Factor XIII - Plasma Derived

Lot No

13

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

### **II.2.4) Description of the procurement**

CM/PHS/22/5561/13 Factor XIII - Plasma Derived

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/14 Factor XIII - Recombinant

Lot No



14

## **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

## **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

## **II.2.4) Description of the procurement**

CM/PHS/22/5561/14 Factor XIII - Recombinant

## **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

## **II.2.6) Estimated value**

Value excluding VAT: £1

## **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/15 Von willebrands factor / Factor VIII

Lot No

15

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

### **II.2.4) Description of the procurement**

CM/PHS/22/5561/15 Von willebrands factor / Factor VIII

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/16 Von willebrands factor - Plasma Derived

Lot No

16

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

### **II.2.4) Description of the procurement**

CM/PHS/22/5561/16 Von willebrands factor - Plasma Derived

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/17 Von willebrands factor - Recombinant

Lot No

17

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

#### **II.2.4) Description of the procurement**

CM/PHS/22/5561/17 Von willebrands factor - Recombinant

#### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

#### **II.2.6) Estimated value**

Value excluding VAT: £1

#### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

#### **II.2.10) Information about variants**

Variants will be accepted: No

#### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/18 Fibrinogen Concentrate

Lot No

18

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

### **II.2.4) Description of the procurement**

CM/PHS/22/5561/18 Fibrinogen Concentrate

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/19 Prothrombin Complex dried

Lot No



19

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

### **II.2.4) Description of the procurement**

CM/PHS/22/5561/19 Prothrombin Complex dried

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/20 Protein C Concentrate

Lot No

20

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

### **II.2.4) Description of the procurement**

CM/PHS/22/5561/20 Protein C Concentrate

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/21 Fresh Frozen Plasma (all blood groups)

Lot No

21

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

### **II.2.4) Description of the procurement**

CM/PHS/22/5561/21 Fresh Frozen Plasma (all blood groups)

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/22 Freeze Dried Plasma

Lot No

22

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

#### **II.2.4) Description of the procurement**

CM/PHS/22/5561/22 Freeze Dried Plasma

#### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

#### **II.2.6) Estimated value**

Value excluding VAT: £1

#### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

#### **II.2.10) Information about variants**

Variants will be accepted: No

#### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

CM/PHS/22/5561/23 Caplacizumab

Lot No

23

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

### **II.2.4) Description of the procurement**

CM/PHS/22/5561/23 Caplacizumab

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No



---

## **Section III. Legal, economic, financial and technical information**

### **III.1) Conditions for participation**

#### **III.1.2) Economic and financial standing**

Selection criteria as stated in the procurement documents

---

## **Section IV. Procedure**

### **IV.1) Description**

#### **IV.1.1) Type of procedure**

Open procedure

#### **IV.1.3) Information about a framework agreement or a dynamic purchasing system**

The procurement involves the establishment of a framework agreement

Framework agreement with several operators

#### **IV.1.8) Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: Yes

### **IV.2) Administrative information**

#### **IV.2.2) Time limit for receipt of tenders or requests to participate**

Date

21 March 2024

Local time

1:00pm

#### **IV.2.4) Languages in which tenders or requests to participate may be submitted**

English

#### **IV.2.6) Minimum time frame during which the tenderer must maintain the tender**

Tender must be valid until: 19 June 2024

#### **IV.2.7) Conditions for opening of tenders**

Date

21 March 2024

Local time

1:00pm

Place

Runcorn

Information about authorised persons and opening procedure

Medicines Procurement and Supply Chain Employee

---

### **Section VI. Complementary information**

#### **VI.1) Information about recurrence**

This is a recurrent procurement: No

#### **VI.2) Information about electronic workflows**

Electronic ordering will be used

Electronic invoicing will be accepted

Electronic payment will be used

#### **VI.3) Additional information**

## RESPONDING TO THIS NOTICE;

Any supplier may be disqualified who does not respond to the following in the requisite manner:

1) Submission of expression of interest and procurement specific information. This procurement exercise will be conducted on the eTendering portal at

<http://health.atamis.co.uk>

Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested) through the eTendering portal as follows:

1.1) If not already registered, Candidates should register on the eTendering portal at

<http://health.atamis.co.uk> and click the link to register:

- agree to the user agreement
- populate company details

1.2) Once registered, candidates must register interest as follows:

- log to the portal
- select "Find Opportunities" from the supplier home screen, use the "Sort by:" facility to find this opportunity and select the bold blue title to select
- review opportunity details and click "Register Interest"
- as you select the opportunity, you can review documents, send clarification messages, submit the response or decline to respond (if you decide not to participate in the opportunity)

1.3) There is a supplier user guide on using the system and Candidates can contact the Atamis helpdesk at [supporthealth@atamis.co.uk](mailto:supporthealth@atamis.co.uk) or by calling 0800 9956035 for technical assistance when completing responses.

2) General supplier information.

To manage and assess supplier information the Contracting Authority requests candidates provide their

company profile in the Government's Supplier Registration Service (which has replaced sid4gov), as follows:

2.1) If not already registered (the previous sid4gov password, login and details will still be on the system), candidates must go to the following web page

<https://supplierregistration.cabinetoffice.gov.uk>

and select "Register" at the top of the page.

Key in details as requested to search for your company. If you do not have a D-U-N-S® Number, click on the link at the right of the page to obtain a number from D&B.

Candidates must obtain a Dun & Bradstreet (D&B) D-U-N-S® Number to enable registration on the system.

2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise.

D&B data will be supplied automatically by D&B.

2.3) For further help or information concerning this telephone +44 (0) 161 413 7982 or via the

message function on the website.

#### OTHER CONTRACTING AUTHORITIES

The framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.

## **VI.4) Procedures for review**

### **VI.4.1) Review body**

The High Court

The Strand

London

WC2A 2LL

Country

United Kingdom

Internet address

<https://www.judiciary.uk/courts-and-tribunals/high-court/>